Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc.

In a report released today, Eliana Merle from Barclays maintained a Hold rating on Moderna, with a price target of $48.00. Merle covers the Healthc...

Barclays Reaffirms Their Hold Rating on Moderna (MRNA)

Shares in Moderna ($MRNA) tumbled by 12% on Friday afternoon after JPMorgan ($JPM) reaffirmed its Sell rating on the U.S. pharma and biotech compan...

Here’s Why Moderna Stock (MRNA) Is Crashing Today — July 10, 2026

An update from Moderna ( ($MRNA) ) is now available. On July 6, 2026, Moderna’s Board of Directors appointed veteran financial executive Michael Mc...

Moderna Strengthens Board with New Financial Director

Moderna ( ($MRNA) ) has risen by 14.43%. Read on to learn why. Moderna shares extended their recent rally this week, rising 14.43% as investors lat...

Moderna’s Pipeline Hype Sends Shares Soaring Again

Moderna ( ($MRNA) ) has risen by 13.36%. Read on to learn why. Moderna shares continued their recent rally this week, climbing 13.36% as investors ...

Moderna’s Surprise Surge: Is the mRNA Giant Back?

Moderna ($MRNA) stock jumped nearly 15% at one point on Friday to around $69 per share after investors reacted positively to the biotech firm’s lat...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRNA	$54.07	-5.17%	4.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRNA	$54.07	-5.2%	4.42M
3
4
5
6

MRNA

MRNA

Get Moderna Inc. Data in Excel

Get Moderna Inc. Data in Excel